Clinical Trials Logo

CML, Chronic Phase clinical trials

View clinical trials related to CML, Chronic Phase.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06409936 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

PEARL
Start date: September 2024
Phase: Phase 2
Study type: Interventional

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B). All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily. The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.

NCT ID: NCT06121765 Not yet recruiting - CML, Chronic Phase Clinical Trials

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

Start date: November 1, 2023
Phase:
Study type: Observational

Metabolic alternation and clinicohematological characteristic in chronic phase CML in patient treated with TKI

NCT ID: NCT05367765 Not yet recruiting - CML, Chronic Phase Clinical Trials

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Start date: April 30, 2022
Phase: Phase 4
Study type: Interventional

Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).